49 completed. 49 Phase 3, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 49 | Completed 49 |
| Phase 2 | 7 | Completed 7 |
Follow Sofosbuvir: new trials by email Literature Review of Sofosbuvir trials Research Report on Sofosbuvir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C Sofosbuvir 400 MG, Ravidasvir 200mg - Hepatitis C | Phase 2 / Phase 3 | Completed | Muhammad Radzi Abu Hassan | 322 | 2021-03-23 | 2025-03-13 |
| Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment Sofosbuvir plus Ledipasvir - Covid19 | Phase 3 | Completed | Almaza Military Fever Hospital | 250 | 2020-04-15 | 2020-08-28 |
| Utilization of Hepatitis C Positive Kidneys in Negative Recipients Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET] - Kidney Transplant, Hepatitis C | Phase 2 / Phase 3 | Completed | Ohio State University | 54 | 2019-03-22 | 2023-09-13 |
| Safety of Sofosbuvir in People With Advanced Kidney Failure Sofosbuvir, Daclatasvir 60 mg - Kidney Failure, Chronic, Hepatitis C | Phase 3 | Completed | Sanjay Gandhi Postgraduate Institute of Medical Sciences | 30 | 2019-03-15 | 2021-04-06 |
| Phase 3 Study of Yimitasvir Phosphate Capsules SOF, DAG181 - Chronic HCV Infection | Phase 3 | Completed | Sunshine Lake Pharma Co., Ltd. | 362 | 2018-04-17 | 2020-03-18 |
| Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C] Sofosbuvir, Daclatasvir, Pegylated Interferon alfa-2a - Hepatitis C, Chronic | Phase 2 / Phase 3 | Completed | Johns Hopkins Bloomberg School of Public Health | 150 | 2018-02-02 | 2021-05-18 |
| Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination Simvastatin 10mg, sofosbuvir plus daclatasvir - Chronic Hepatitis c, Metabolic Syndrome | Phase 2 / Phase 3 | Completed | Ain Shams University | 100 | 2017-12-01 | 2018-09-20 |
| KW-136 With Sofosbuvir for Chinese Adults With Chronic Hepatitis C KW-136 capsule, Sofosbuvir - Hepatitis C, Chronic | Phase 3 | Completed | Kawin Technology Share-holding Co., Ltd. | 371 | 2017-06-07 | 2019-06-25 |
| Treatment of Egyptian Hepatitis C Genotype 4 Infected Children (and Adolescents) With Combined Sofosbuvir & Daclatasvir Combined Therapy SOF and DCV - Hepatitis C Genotype 4 | Phase 3 | Completed | Yassin Abdelghaffar Charity Center for Liver Disease and Research | 40 | 2017-03-18 | 2018-06-06 |
| Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection. SOF/VEL for 6 weeks, SOF/VEL for 12 weeks - Hepatitis C | Phase 3 | Completed | Kirby Institute | 222 | 2017-03-09 | 2021-11-24 |
| Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus sofosbuvir and daclatasvir - Hepatitis C Virus Infection, Response to Therapy of, Human Immunodeficiency Virus | Phase 3 | Completed | Tehran University of Medical Sciences | 232 | 2017-01-01 | 2019-02-20 |
| Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study Sofosbuvir, Glecaprevir/Pibrentasvir, Ribavirin - Hepatitis C Virus Infection | Phase 3 | Completed | AbbVie | 33 | 2016-11-21 | 2022-05-04 |
| A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection Dactavira Plus, Sofosbuvir + Daclatasvir + Ribavirin, Dactavira - Hepatitis C | Phase 3 | Completed | Egyptian Liver Hospital | 72 | 2016-09-01 | 2017-12-27 |
| Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1 Sofosbuvir, Ledipasvir, Ribavirin - Hepatitis C, Cirrhosis | Phase 3 | Completed | Tehran University of Medical Sciences | 50 | 2016-09-01 | 2018-04-30 |
| Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection LDV/SOF, SOF, RBV - Hepatitis C Virus Infection | Phase 3 | Completed | Gilead Sciences | 239 | 2016-04-12 | 2018-11-16 |
| A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection ABT-493/ABT-530, sofosbuvir (SOF), ribavirin (RBV) - Chronic Hepatitis C Virus, Hepatitis C Virus | Phase 3 | Completed | AbbVie | 136 | 2016-04-08 | 2021-07-16 |
| Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC Sofosbuvir, Ribavirin, Simeprevir - Hepatitis C, Chronic, Hepatocellular Carcinoma | Phase 3 | Completed | National Hepatology & Tropical Medicine Research Institute | 150 | 2016-03-01 | 2026-04-13 |
| A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection ABT-493/ABT-530, Sofosbuvir, Daclatasvir - Chronic Hepatitis C, Hepatitis C Virus | Phase 3 | Completed | AbbVie | 506 | 2015-12-01 | 2021-07-30 |
| Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics Sofosbuvir, Daclatasvir, Ribavirin - Hepatitis C, Cirrhosis | Phase 3 | Completed | Tehran University of Medical Sciences | 100 | 2015-09-01 | 2023-04-20 |
| Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Tablet Plus Ribavirin Tablet (Part A) Versus Single Dose (2 Tablets) of EHCV Containing Sofosbuvir, Ribavirin, and Natural Anti-hemolytic (B) in Egyptian Adults With Chronic Genotype 4 HCV Infection Two tablets of EHCV in Single Dose each tablet containing SOF 200 mg, RBV 500 mg and Natural anti-hemolytic (AH) at 200 mg, Sofosbuvir tablet (SOF) 400 mg - once daily, Ribavirin (RBV) 1000 mg - splitted on 2 doses daily - 600 mg on morning and 400 mg on evening - Hepatitis c | Phase 2 / Phase 3 | Completed | Egyptian Liver Hospital | 80 | 2015-07-01 | 2016-10-17 |
Showing 20 of 49. Sign in to see all of them.
Hepatitis C (30) · Hepatitis C, Chronic (15) · Fibrosis (6) · Acquired Immunodeficiency Syndrome (3) · Bronchiolitis Obliterans Syndrome (1) · COVID-19 (1) · Carcinoma, Hepatocellular (1) · Digestive System Diseases (1) · Directly Observed Therapy (1) · Enterovirus Infections (1) · Flaviviridae Infections (1) · Hepatitis (1) · Hepatitis, Chronic (1) · Hepatitis, Viral, Human (1) · Kidney Failure, Chronic (1)
Gilead Sciences (18) · AbbVie (4) · Bristol-Myers Squibb (4) · Humanity and Health Research Centre (3) · Tehran University of Medical Sciences (3) · Egyptian Liver Hospital (2) · Janssen Infectious Diseases BVBA (2) · Ain Shams University (1) · Almaza Military Fever Hospital (1) · Janssen R&D Ireland (1) · Johns Hopkins Bloomberg School of Public Health (1) · Kawin Technology Share-holding Co., Ltd. (1) · Kirby Institute (1) · Merck Sharp & Dohme LLC (1) · Muhammad Radzi Abu Hassan (1)
United States (17) · Canada (10) · Australia (9) · Puerto Rico (9) · New Zealand (8) · China (7) · Egypt (7) · United Kingdom (7) · Germany (6) · France (5) · Italy (5) · Spain (5) · Netherlands (4) · Sweden (4) · India (3)
Anuj Gaggar, MD, PhD (2) · Kathryn Kersey, MSc (2) · Reza Malekzadeh, M.D. (2) · Steven Knox (2) · Aisha El Sharkawy, MD (1) · Amit Goel, DM (1) · Amr Maged (1) · Anu Osinusi, MD (1) · Bittoo Kanwar, MD (1)
PMID 25040192, PMID 25583164, PMID 23607593, PMID 23607594, PMID 26575258, PMID 27847279, PMID 36740893, PMID 24316172, PMID 24795201, PMID 25038354, PMID 25614962, PMID 25659285, PMID 25863559, PMID 26196502, PMID 26248087, PMID 26503414, PMID 26743093, PMID 26799692, PMID 26835876, PMID 26864153, PMID 27025835, PMID 27188960, PMID 27376706, PMID 27542322, PMID 27896822, PMID 27933698, PMID 29180522, PMID 29344726, PMID 29404492, PMID 29461687, PMID 29727383, PMID 30012435, PMID 30529905, PMID 30587935, PMID 30868245, PMID 30923816, PMID 30977945, PMID 31568620, PMID 33633233, PMID 33930223, PMID 34023350, PMID 37675828, PMID 42140479, PMID 42277657
2014 (4), 2015 (1), 2016 (1), R01DA026727 (1)